4 news items
Praxis Precision Medicines Advances Precision Therapies for CNS Disorders, Anticipates Key Milestones in Seizure and Pediatric Epilepsy Treatment
PRAX
13 May 24
arms, combined with a favorable tolerability and safety profile, builds confidence in our planned focal onset seizure studies for PRAX-628
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
PRAX
12 Apr 24
-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide: The Future of Clinical Trial Design in Essential
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday
PRAX
26 Mar 24
of response across both study arms, combined with a continued positive tolerability and safety profile, build on our earlier conviction that PRAX-628 has
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
ACET
CPRX
EXAI
21 Mar 24
-precision-medicines-safety-shot-catalyst-pharmaceuticals-adicet-bio-or-exscientia-302095927.html
SOURCE InvestorsObserver
- Prev
- 1
- Next